← Back to patent-cliff list
CAS 2730018-14-9
(3aS,5S,8R,9aS,10S,12S,13aR,13bS)-12-Hydroxy-6,9a,14,14-tetramethyl-13-methylidene-2,9-dioxo-10-[(triethylsilyl)oxy]-5-[(trimethylsilyl)oxy]-5,8,9,9a,10,11,12,13,13a,13b-decahydro-2H,4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxol-8-yl acetate
Codes：(XXIV)101438-71-c
Application context (from source-drug indications)
乳腺癌Paclitaxel/Encequidar mesylate腺癌Paclitaxel/Encequidar mesylate血管肉瘤Paclitaxel/Encequidar mesylate实体瘤Paclitaxel/Encequidar mesylate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Paclitaxel/Encequidar mesylatePaclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
Acetic acid acetic anhydride→(3aS,5S,8R,9aS,10S,13bS)-6,9a,13,14,14-Pentamethyl-12-[2-(4-methylbenzene-1-sulfonyl)hydrazinylidene]-2,9-dioxo-10-[(triethylsilyl)oxy]-5-[(trimethylsilyl)oxy]-5,8,9,9a,10,11,12,13b-octahydro-2H,4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxol-8-yl acetate→(3aS,5S,8R,9aS,10S,13aR,13bS)-6,9a,13,14,14-Pentamethyl-2,9-dioxo-10-[(triethylsilyl)oxy]-5-[(trimethylsilyl)oxy]-5,8,9,9a,10,11,13a,13b-octahydro-2H,4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxol-8-yl acetate→(3aS,5S,8R,9aS,10S,12S,13aR,13bS)-12-Hydroxy-6,9a,14,14-tetramethyl-13-methylidene-2,9-dioxo-10-[(triethylsilyl)oxy]-5-[(trimethylsilyl)oxy]-5,8,9,9a,10,11,12,13,13a,13b-decahydro-2H,4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxol-8-yl acetate→(3R,4S)-1-Benzoyl-4-phenyl-3-(triethylsiloxy)azetidin-2-one→(3aS,5S,8R,9aS,10S,12S,13aR,13bS)-12-[(Methanesulfonyl)oxy]-6,9a,14,14-tetramethyl-13-methylidene-2,9-dioxo-10-[(triethylsilyl)oxy]-5-[(trimethylsilyl)oxy]-5,8,9,9a,10,11,12,13,13a,13b-decahydro-2H,4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxol-8-yl acetate→(3aS,5S,8R,9aS,10S,12S,13S,13aR,13bS)-13-Hydroxy-13-(hydroxymethyl)-12-[(methanesulfonyl)oxy]-6,9a,14,14-tetramethyl-2,9-dioxo-10-[(triethylsilyl)oxy]-5-[(trimethylsilyl)oxy]-5,8,9,9a,10,11,12,13,13a,13b-decahydro-2H,4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxol-8-yl acetate→(3aS,5S,8R,9aS,10S,11aR,13aS,13bR,13cS)-5-Hydroxy-6,9a,14,14-tetramethyl-2,9-dioxo-10-[(triethylsilyl)oxy]-4,5,8,9,9a,10,11,11a,13b,13c-decahydro-2H-3a,7-methano[1,3]dioxolo[9,10]cyclodeca[1,2-d][1]benzoxete-8,13a(13H)-diyl diacetate→Dilithium (3aS,5S,8R,9aS,10S,11aR,13aS,13bR,13cS)-8,13a-bis(acetyloxy)-6,9a,14,14-tetramethyl-9-oxo-2-phenyl-10-[(triethylsilyl)oxy]-4,5,8,9,9a,10,11,11a,13,13a,13b,13c-dodecahydro-2H-3a,7-methano[1,3]dioxolo[9,10]cyclodeca[1,2-d][1]benzoxete-2,5-bis(olate)
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.